CoChat

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Sasikumar, Pottayil G., Ramachandra, Raghuveer K., Adurthi, Srinivas, Dhudashiya, Amit A., Vadlamani, Sureshkumar, Vemula, Koteswararao, Vunnum, Sriharibabu, Satyam, Leena K., Samiulla, Dodderi S., Subbarao, Krishnaprasad, Nair, Rashmi, Shrimali, Rajeev, Gowda, Nagaraj, Ramachandra, Murali · 2019 · Molecular Cancer Therapeutics
Cited by 61

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Pioneering success of antibodies targeting immune checkpoints such as PD-1 and CTLA4 has opened novel avenues for cancer immunotherapy. Along with impressive clinical activity, severe immune-related adverse events (irAE) due to the breaking of immune self-tolerance are becoming increasingly evident in antibody-based approaches. As a strategy to better manage severe adverse effects, we set out to discover an antagonist targeting PD-1 signaling pathway with a shorter pharmacokinetic profile. Herein, we describe a peptide antagonist NP-12 that displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. In preclinical models of melanoma, colon cancer, and kidney cancers, NP-12 showed significant efficacy comparable with commercially available PD-1–targeting antibodies in inhibiting primary tumor growth and metastasis. Interestingly, antitumor activity of NP-12 in a preestablished CT26 model correlated well with pharmacodynamic effects as indicated by intratumoral recruitment of CD4 and CD8 T cells, and a reduction in PD-1+ T cells (both CD4 and CD8) in tumor and blood. In addition, NP-12 also showed additive antitumor activity in preestablished tumor models when combined with tumor vaccination or a chemotherapeutic agent such as cyclophosphamide known to induce “immunologic cell death.” In summary, NP-12 is the first rationally designed peptide therapeutic targeting PD-1 signaling pathways exhibiting immune activation, excellent antitumor activity, and potential for better management of irAEs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-18-0737

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 61

Metadata

Authors
Sasikumar, P. G., Ramachandra, R. K., Adurthi, S., Dhudashiya, A. A., Vadlamani, S., Vemula, K., Vunnum, S., Satyam, L. K., Samiulla, D. S., Subbarao, K., Nair, R., Shrimali, R., Gowda, N., & Ramachandra, M.
Venue
Molecular Cancer Therapeutics
Published
2019-06-01
Volume
18
Issue
6
Pages
1081-1091
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2942140928
Cited by
61
References
3
FWCI
2.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-0737
The paper
Sasikumar, P. G., Ramachandra, R. K., Adurthi, S., Dhudashiya, A. A., Vadlamani, S., Vemula, K., Vunnum, S., Satyam, L. K., Samiulla, D. S., Subbarao, K., Nair, R., Shrimali, R., Gowda, N., & Ramachandra, M. (2019). A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-0737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.